Literature DB >> 27660275

Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder.

Marcin Siwek1, Magdalena Sowa-Kućma2, Krzysztof Styczeń1, Paulina Misztak2,3, Rafał J Nowak4, Bernadeta Szewczyk2, Dominika Dudek1, Janusz K Rybakowski5, Gabriel Nowak2,3, Michael Maes6,7,8,9,10.   

Abstract

To examine cytokine receptor biomarkers in bipolar disorder (BD), we recruited 133 well-phenotyped BD patients and 50 normal controls and measured serum levels of soluble interleukin 1 receptor antagonist (sIL-1RA), soluble interleukin-2 receptor (sIL-2R), sIL-6R, and tumor necrosis factor receptor 60 and 80 kDa (sTNFR60/80). sIL-1RA and sTNFR80 are significantly higher in BD than in controls and sTNFR80 and higher in melancholic than in non-melancholic patients and controls. Kapczinski's stages 3 + 4 are characterized by lowered sIL-2R and increased sTNFR80 levels. Acute phase depression is characterized by increased sTNFR80 levels as compared with controls, manic, and euthymic patients. Both sTNFR60 and sTNFR80 levels are significantly and positively related with severity of depression but not mania. Logistic regression analysis showed that the significant predictors for BD are increased sIL-1RA levels, nicotine dependence and a family history of depression and alcoholism. The risk factors for stages 3 + 4 are lowered sIL-2R levels and nicotine dependence. Melancholia is predicted by higher sTNFR80 levels and female sex. Severity of depression is predicted by female sex, nicotine dependence, and increased sTNFR60 and sTNFR80 levels. Cell-mediated immunity is activated during a current episode of depression but not (hypo)mania or the euthymic state. There are no associations between the biomarkers and age at onset, duration of illness, severity of mania, bipolar (BP)2 or BP1 subtypes, rapid cycling, atypical depression, psychotic or suicidal symptoms, and a family history of psychiatric disease. The results show that increased sIL-1RA may be a trait marker of BD, increased sTNFR80 a state marker of the depressive phase, especially melancholia, while lower sIL-2R but higher sTNFR80 may be staging biomarkers.

Entities:  

Keywords:  Bipolar; Cytokines; Depression; Immune; Inflammation; Melancholia; Suicide

Mesh:

Substances:

Year:  2016        PMID: 27660275     DOI: 10.1007/s12035-016-0124-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  34 in total

1.  Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.

Authors:  Sinead M O'Brien; Paul Scully; Lucinda V Scott; Timothy G Dinan
Journal:  J Affect Disord       Date:  2006-01-10       Impact factor: 4.839

2.  Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features.

Authors:  Dalibor Karlović; Alessandro Serretti; Nada Vrkić; Marko Martinac; Darko Marčinko
Journal:  Psychiatry Res       Date:  2012-03-03       Impact factor: 3.222

3.  Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder.

Authors:  Yong-Ku Kim; Hyun-Gang Jung; Aye-Mu Myint; Hyun Kim; Sun-Hwa Park
Journal:  J Affect Disord       Date:  2007-04-16       Impact factor: 4.839

4.  A rating scale for mania: reliability, validity and sensitivity.

Authors:  R C Young; J T Biggs; V E Ziegler; D A Meyer
Journal:  Br J Psychiatry       Date:  1978-11       Impact factor: 9.319

5.  Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder.

Authors:  Ozge Doganavsargil-Baysal; Buket Cinemre; Umut Mert Aksoy; Halide Akbas; Ozmen Metin; Cıgıl Fettahoglu; Zehra Gokmen; Fatih Davran
Journal:  Hum Psychopharmacol       Date:  2013-03       Impact factor: 1.672

6.  The association between serum levels of neopterin and number of depressive episodes of major depression.

Authors:  Cemil Celik; Murat Erdem; Tuncer Cayci; Barbaros Ozdemir; E Ozgur Akgul; Yasemin Gulcan Kurt; Halil Yaman; Mehmet Isintas; Fuat Ozgen; Aytekin Ozsahin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-01-13       Impact factor: 5.067

7.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.

Authors:  M Maes; E Bosmans; J Calabrese; R Smith; H Y Meltzer
Journal:  J Psychiatr Res       Date:  1995 Mar-Apr       Impact factor: 4.791

8.  Clinical implications of a staging model for bipolar disorders.

Authors:  Flávio Kapczinski; Vasco Videira Dias; Marcia Kauer-Sant'Anna; Benicio Noronha Frey; Rodrigo Grassi-Oliveira; Francesc Colom; Michael Berk
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

Review 9.  The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence.

Authors:  Sandra Odebrecht Vargas Nunes; Heber Odebrecht Vargas; Eduardo Prado; Decio Sabbatini Barbosa; Luiz Picoli de Melo; Steven Moylan; Seetal Dodd; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2013-05-06       Impact factor: 8.989

10.  Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder.

Authors:  Elisa Brietzke; Laura Stertz; Brisa Simões Fernandes; Marcia Kauer-Sant'anna; Marcello Mascarenhas; Andréia Escosteguy Vargas; José Artur Chies; Flávio Kapczinski
Journal:  J Affect Disord       Date:  2009-02-28       Impact factor: 4.839

View more
  15 in total

Review 1.  Low Vs. High Alcohol: Central Benefits Vs. Detriments.

Authors:  Yousef Tizabi; Bruk Getachew; Clifford L Ferguson; Antonei B Csoka; Karl M Thompson; Alejandra Gomez-Paz; Jana Ruda-Kucerova; Robert E Taylor
Journal:  Neurotox Res       Date:  2018-01-04       Impact factor: 3.911

2.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach.

Authors:  Michael Maes; Juliana Brum Moraes; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Ana Paula Michelin; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

3.  Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present.

Authors:  Denitsa Simeonova; Drozdstoy Stoyanov; Jean-Claude Leunis; Andre F Carvalho; Marta Kubera; Marianna Murdjeva; Michael Maes
Journal:  Neurotox Res       Date:  2019-12-04       Impact factor: 3.911

4.  Levels of TNF alpha, Soluble TNF Receptors (sTNF-R1, sTNF-R2) in Bipolar Disorder.

Authors:  Özge Doğanavşargil Baysal; Ali Erdoğan; Buket Cinemre; Halide Akbaş; Semiha Şen Kaya; Sema Kuş
Journal:  Noro Psikiyatr Ars       Date:  2019-10-23       Impact factor: 1.339

5.  TNF-α and its soluble receptors mediate the relationship between prior severe mood episodes and cognitive dysfunction in euthymic bipolar disorder.

Authors:  C E Millett; J Harder; J J Locascio; M Shanahan; G Santone; R N Fichorova; A Corrigan; C Baecher-Allan; K E Burdick
Journal:  Brain Behav Immun       Date:  2020-04-06       Impact factor: 7.217

Review 6.  Secondary Mania induced by TNF-α inhibitors: A systematic review.

Authors:  Alessandro Miola; Veronica Dal Porto; Nicola Meda; Giulia Perini; Marco Solmi; Fabio Sambataro
Journal:  Psychiatry Clin Neurosci       Date:  2021-11-02       Impact factor: 12.145

Review 7.  Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications.

Authors:  Joshua D Rosenblat; Roger S McIntyre
Journal:  Brain Sci       Date:  2017-10-30

8.  Classification of patients with bipolar disorder using k-means clustering.

Authors:  Lorena de la Fuente-Tomas; Belen Arranz; Gemma Safont; Pilar Sierra; Monica Sanchez-Autet; Ana Garcia-Blanco; Maria P Garcia-Portilla
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

9.  Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.

Authors:  Masoud Kamali; Samantha Pegg; Jessica A Janos; William V Bobo; Benjamin Brody; Keming Gao; Terence A Ketter; Susan L McElroy; Melvin G McInnis; Dustin J Rabideau; Noreen A Reilly-Harrington; Richard C Shelton; Louisa G Sylvia; Mauricio Tohen; Andrew Nierenberg
Journal:  J Psychiatr Res       Date:  2021-06-02       Impact factor: 5.250

10.  Markers of Inflammation and Monoamine Metabolism Indicate Accelerated Aging in Bipolar Disorder.

Authors:  Seline van den Ameele; Dietmar Fuchs; Violette Coppens; Peter de Boer; Maarten Timmers; Bernard Sabbe; Manuel Morrens
Journal:  Front Psychiatry       Date:  2018-06-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.